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OBJECTIVES Since B-type natriuretic peptide (BNP) is secreted by the left ventricle (LV) in response to
volume elevated LV pressure, we sought to assess whether a rapid assay for BNP levels could
differentiate cardiac from pulmonary causes of dyspnea.
BACKGROUND Differentiating congestive heart failure (CHF) from pulmonary causes of dyspnea is very
important for patients presenting to the emergency department (ED) with acute dyspnea.
METHODS B-natriuretic peptide levels were obtained in 321 patients presenting to the ED with acute
dyspnea. Physicians were blinded to BNP levels and asked to give their probability of the
patient having CHF and their final diagnosis. Two independent cardiologists were blinded to
BNP levels and asked to review the data and evaluate which patients presented with heart
failure. Patients with right heart failure from cor pulmonale were classified as having CHF.
RESULTS Patients with CHF (n 134) had BNP levels of 758.5 798 pg/ml, significantly higher than
the group of patients with a final diagnosis of pulmonary disease (n  85) whose BNP was
61  10 pg/ml. The area under the receiver operating curve, which plots sensitivity versus
specificity for BNP levels in separating cardiac from pulmonary disease, was 0.96 (p 0.001).
A breakdown of patients with pulmonary disease revealed: chronic obstructive pulmonary
disease (COPD): 54 71 pg/ml (n 42); asthma: 27 40 pg/ml (n 11); acute bronchitis:
44  112 pg/ml (n  14); pneumonia: 55  76 pg/ml (n  8); tuberculosis: 93  54 pg/ml
(n  2); lung cancer: 120  120 pg/ml (n  4); and acute pulmonary embolism: 207 
272 pg/ml (n  3). In patients with a history of lung disease but whose current complaint of
dyspnea was seen as due to CHF, BNP levels were 731  764 pg/ml (n  54). The group with
a history of CHF but with a current COPD diagnosis had a BNP of 47  23 pg/ml (n  11).
CONCLUSIONS Rapid testing of BNP in the ED should help differentiate pulmonary from cardiac etiologies
of dyspnea. (J Am Coll Cardiol 2002;39:202–9) © 2002 by the American College of
Cardiology
Rapidly and accurately determining the etiology of short-
ness of breath in patients presenting with acute dyspnea is
extremely important. The two chief causes of dyspnea,
congestive heart failure (CHF) and lung disease, are often
difficult to differentiate. Physical exam findings, lab tests
and chest X-rays are often nonspecific (1,2). A blood test
that could easily, rapidly and accurately help in diagnosing
CHF would be of great use, especially in the emergency
department (ED).
B-type natriuretic peptide (BNP) is a neurohormone
secreted mainly in the cardiac ventricles in response to
volume expansion and pressure overload (3–6). B-type
natriuretic peptide levels are elevated in patients with left
ventricular (LV) dysfunction and correlated to the severity
as well as prognosis (7–11). In a recent pilot trial, BNP
levels obtained by a rapid assay were able to accurately detect
CHF in patients presenting with dyspnea (12). The purpose
of the present study was to determine if BNP levels could
accurately differentiate CHF from dyspnea of pulmonary
etiologies.
METHODS
This study was approved by the University of California
Institutional Review Board. A convenience sample of 321
patients presenting to urgent care with dyspnea was re-
cruited June 1999 through June 2000 at the San Diego
Veteran’s Health Care System. To be eligible for the study,
the patient had to have shortness of breath—either at rest,
with exertion or upon lying down—as a prominent com-
plaint. Other associated symptoms could be edema, weight
gain, cough or wheezing. Patients whose dyspnea was
clearly not secondary to CHF (knife wounds, trauma and
cardiac tamponade) were excluded. Patients with unstable
angina or acute myocardial infarction were excluded unless
their predominant presentation was dyspnea. To identify
potential patients, a physician or a trained research assistant
reviewed nurse descriptions of patients’ principal com-
plaints. Patients fitting the above criteria were queried
regarding participation in the study. The rate of refusal of
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patients approached for entry was5%. When a patient was
identified as possibly having CHF, consent was obtained
and a blood sample was collected for purposes of measuring
the patient’s BNP. The research assistant collected other
data, including elements from the present and past history,
the physical exam and the patients’ medications. Patients
with right heart failure from cor pulmonale were classified as
having CHF.
Confirmation of the diagnosis.
1. CHF: The diagnosis of CHF was based on independent
confirmation of two cardiologists and was based on
generally accepted Framingham criteria (9) with corrob-
orative information including hospital course (response
to diuretics, vasodilators, inotropes or hemodynamic
monitoring) and results of further cardiac testing, includ-
ing echocardiography, nuclear medicine ejection frac-
tions or left ventriculography done at cardiac catheter-
ization.
2. Baseline LV dysfunction with no acute CHF: based on the
known past history (confirmed by ventricular function
studies) whose final cause of acute dyspnea was not
CHF.
3. Pulmonary disease: the following diagnostic tools were
utilized to classify a patient as having pulmonary disease
and to subdivide them as type of pulmonary disease: 1) a
chest X-ray without signs of heart enlargement or
pulmonary venous hypertension or a chest X-ray with
signs of chronic obstructive lung disease, pneumonia or
lung cancer; 2) normal heart function as seen by echo-
cardiography, nuclear medicine, ejection fractions or left
ventriculography; 3) abnormal pulmonary function tests
or follow-up results in pulmonary clinic; 4) a positive
response to treatment with steroids, neubilizers or anti-
biotics in the ED or hospital; and 5) no admissions for
CHF over the next 30 days. Chest X-rays that were
performed within 30 days of presentation to the ED
were used in reporting and analysis of the data. Either
high-probability ventilation perfusion scan or pulmonary
angiography confirmed pulmonary embolism.
4. Cardiac problems other than CHF: this included patients
whose primary complaints turned out to be secondary to
angina pectoris or atypical chest pain.
5. Other problems that were not considered to be of cardiac or
pulmonary etiology: patients that were placed into the
other category were diagnosed with such problems as,
but not limited to, anxiety or psychological stress, gas-
troesophageal reflux disease, allergic reaction or cirrhosis.
There were some patients whose dyspnea was not due to
a CHF exacerbation, yet they were noted to have an
underlying type of LV dysfunction. This was an addi-
tional categorization above and beyond one of the
diagnostic four they were placed into.
Measurement of BNP plasma levels. All samples were
collected by venipuncture into ethylene diamine tetra acetic
acid (EDTA) tubes. The blood samples were kept at room
temperature and analyzed within 4 h of the draw time.
Before analysis, each tube was inverted several times to
ensure homogeneity. The whole blood was then analyzed in
triplicate with the Triage BNP assay. In some cases, the
sample was centrifuged and plasma was removed, aliquioted
and frozen at 70°C before analysis. The BNP assay is a
sandwich immunoassay that consists of a disposable device
to which 250 l of EDTA-anticoagulated whole blood or
plasma is added. The Triage Meter is used to measure the
BNP concentration by detecting a fluorescent signal that
reflects the amount of BNP in the sample.
Once 250 l of whole blood or plasma was added to the
device, the cells were separated from the plasma by a filter
and the plasma containing BNP entered a reaction chamber
that contained fluorescent-tagged BNP antibodies to form a
reaction mixture. The reaction mixture was incubated for
about 2 min and then migrated through the diagnostic lane
by capillary action to a zone of immobilized antibody that
binds the desired BNP-fluorescent antibody complex. The
excess sample fluid washed the unbound fluorescent anti-
bodies away. After about 15 min, the device was placed into
the Triage Meter, which measures the fluorescence intensity
of the BNP assay zone. The Triage Meter then correlated
the fluorescence measurement to the BNP concentration by
using an internal calibration curve. The assay was completed
in approximately 15 min.
PRECISION. The coefficient of variation (CV) for intra-
assay precision is 9.5% for 28.8 ng/l, 12.0% for 584 ng/l and
13.9% for 1,180 ng/l. The CV for interassay variation is
10% for 28.8 ng/l, 12.4% for 584 ng/l and 14.8% for
1,180 ng/l. B-type natriuretic peptide concentrations mea-
sured in plasma and whole blood are also not significantly
different (y  0.925x  13.439, r  0.9878).
ANALYTICAL SENSITIVITY AND DETECTION LIMIT. The an-
alytical sensitivity, the lowest concentration distinguishable
from zero, is5.0 ng/l (95% confidence interval: 0.2 ng/l to
4.8 ng/l). The measurable range of the BNP assay is 5.0 ng/l
to 1,300 ng/l.
INTERFERENCES. Naturally occurring analytes, such as he-
moglobin, triglycerides, cholesterol and bilirubin, do not
interfere with the assay. Several proteins structurally related
to BNP and commonly used therapeutic agents are also
analyzed for possible interference with the BNP assay. None
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CHF  congestive heart failure
COPD  chronic obstructive pulmonary disease
CV  coefficient of variation
ED  emergency department
EDTA  ethylene diamine tetra acetic acid
LV  left ventricle or left ventricular
PEF  peak expiratory flow
ROC  receiver-operating characteristic
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of these compounds produce any interference or significant
assay cross-reactivity.
BNP STABILITY. B-type natriuretic peptide stability varies
between room temperature and 4°C. Concentration differ-
ences are considered significant when there was 15%
difference between the time point and the initial value.
Using these criteria, 100% of the samples are stable up to 8 h
at 4°C. At room temperature, however, three samples are
stable for 8 h, and three samples are stable for 4 h.
Therefore, the minimum stability of BNP at room temper-
ature is determined to be 4 h.
Statistics. Group comparisons of BNP values were made
using t tests for independent samples and analyses of
variance with post-hoc Tukey tests where indicated. In all
cases, these were computed with raw BNP values and
repeated with log-transformed BNP values since the BNP
distribution was positively skewed. Both versions yielded the
same conclusions. Results are expressed as mean  SD for
the raw values. The diagnostic utility of BNP in separating
CHF from other diseases was determined using receiver-
operating characteristic (ROC) curves. The results are
expressed in terms of the area under the curve and the 95%
confidence interval for this area. Sensitivity, specificity and
accuracy were computed for BNP using a selection of
possible cut-points. To evaluate the utility of BNP mea-
surements in the diagnosis of CHF, we compared the
sensitivity, specificity and accuracy of BNP measurements to
individual findings, to a multivariate model of clinical
findings and to clinical judgment. For each of the different
clinical and X-ray findings identified by ED physicians and
different threshold BNP concentrations, we computed sen-
sitivity, specificity and accuracy. Then, to determine if BNP
measurements added independent diagnostic information to
commonly collected clinical variables, we applied multivar-
iate step-wise logistic regression. We developed the best
predictive model based on historical, clinical and X-ray
findings using a p value of 0.1 for entry into the model.
After a stable model was obtained, we added BNP mea-
surements to the predictive model and assessed improve-
ment in the degree of fit.
RESULTS
Table 1 shows the characteristics of the 321 study patients.
A total of 42% had a history of CHF, while 40% had a
history of pulmonary disease. About one-half were on
cardiac drugs and one-half were on pulmonary drugs.
Three-fourths of all patients had dyspnea at rest. Jugular
venous pressure elevation was present in 20% of patients and
wheezing in 29% of patients. Gallops were rare (6%). The
BNP levels were higher in the 139 patients who were
admitted (546  787 pg/ml) than they were in the 181
patients who were not admitted (209  419 pg/ml).
The final diagnosis along with BNP levels of patients is
illustrated in Figure 1. A total of 42% of patients had CHF
as a final diagnosis for their dyspnea. This group had much
higher BNP levels than the 85 patients with a final diagnosis
of pulmonary disease (759  799 pg/ml vs. 61  92 pg/ml,
p  0.001). In patients with baseline LV dysfunction but
whose cause of dyspnea was other than CHF, BNP levels
averaged 149  84 pg/ml. Patients with other types of
cardiac disease or noncardiac, nonpulmonary disease had
BNP levels within the range of normal. Twenty-eight
patients with CHF had a history of chronic obstructive
pulmonary disease (COPD) plus elevated jugular venous
pressure and/or edema. Their mean BNP level was 669 
715 pg/ml.
The ability of BNP to differentiate CHF from pulmonary
disease was assessed with ROC curve analysis (Fig. 2). The
area under the ROC curve using BNP to differentiate CHF
from pulmonary disease was 0.99 (0.96 to 0.99, p  0.001).
A BNP value of 94 pg/ml had a sensitivity of 86%,
specificity of 98% and an accuracy of 91% for differentiating
CHF from pulmonary disease.
Types of pulmonary disease. Figure 3 breaks down the
BNP levels in each classification of pulmonary disease. The
average BNP levels for the majority of the lung categories
are well below those of the CHF group. It is noted that the
BNP levels of the small groups of patients with pulmonary
embolism, lung cancer and tuberculosis were higher than
the rest of the diseases in the pulmonary group. Figure 4
shows BNP levels in patients with a past history of pulmo-
nary disease but a final diagnosis of acute CHF as well as
patients with a past history of CHF but a final diagnosis of
acute pulmonary disease. Those patients with a history of
CHF but whose dyspnea was due to a current COPD
exacerbation (n  11) had an average BNP of 47  23
pg/ml. Those with a history of COPD with a current
Table 1. Patient Characteristics
History of
Congestive heart failure 42%
Hypertension 65%
Coronary artery disease 54%
Coronary artery bypass graft 22%







Dyspnea on exertion 100%
Dyspnea at rest 75%
Orthopnea 29%









ACE  angiotensin-converting enzyme.
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CHF exacerbation (n  54) had an average BNP level of
731  764 pg/ml.
Association between BNP levels and final diagnosis.
Univariate analysis was performed for all variables pertinent
to a diagnosis of CHF or lung disease, along with BNP
concentrations at 80, 100, 120, 140 and 200 pg/ml. The
sensitivity, specificity and accuracy for each variable is
reported in Table 2. The best clinical predictor was a past
history of CHF (79% accuracy) followed by heart size and
pulmonary venous hypertension on chest X-ray (73% and
70% accuracy) and elevated jugular venous pressure (70%
accuracy). B-type natriuretic peptide was an accurate pre-
dictor of patient diagnosis. The negative predictive value of
80 pg/ml was 99%.
In multivariate analyses, we evaluated the combined
explanatory power of history, symptoms, signs, radiological
studies and lab findings (Table 3). The addition of BNP
levels to the regression substantially increased the explana-
tory power of the model, suggesting that BNP measure-
ments provided meaningful diagnostic information not
available from other clinical variables.
DISCUSSION
Because patients with LV dysfunction have improved sur-
vival and increased well-being on medications such as
angiotensin-converting enzyme inhibitors and beta-blockers
(13), it is imperative to make the correct diagnosis as
accurately and as early in the course of the disease as
possible. For the acutely ill patient presenting to the ED, a
misdiagnosis could place the patient at risk for both mor-
bidity and mortality (14). Therefore, the ED diagnosis of
CHF needs to be rapid and accurate.
Dyspnea, the chief symptom in patients with CHF, is
reported to be relevant in 2.7% of ED visits and 15% to 25%
of all hospital admissions (1,2,15,16). To be able to differ-
entiate cardiac from pulmonary causes of dyspnea is a
difficult yet critical aspect of the physician’s job. Yet despite
the tools available to physicians, the differentiation can still
be difficult. A reliable history cannot always be ascertained
in an acutely ill patient, and dyspnea, a key symptom of
CHF, may be a nonspecific finding in the elderly or obese
patient in whom comorbidity with respiratory disease and
physical deconditioning are common (14,17). Physical exam
findings, routine lab values, electrocardiograms and chest
X-rays are also not accurate enough to always make the
appropriate diagnosis (15–19). Echocardiography has lim-
ited availability in acute care settings and may not be helpful
in delineating diastolic dysfunction. Finding a blood test
that would aid in the diagnosis and management of patients
with CHF would clearly have a favorable impact on the
staggering costs associated with the disease (20).
B-type natriuretic peptide is a 32-aa polypeptide contain-
ing a 17-aa ring structure common to all natriuretic peptides
(3,4). Release of BNP appears to be directly proportional to
ventricular volume expansion and pressure overload (3,6,21)
and, hence, has been found to be useful for evaluating
patients with dyspnea or with LV dysfunction (9–12,22–
24). The recent availability of a rapid assay for BNP has
already proven valuable in evaluating the effectiveness of
BNP in point-of-care settings (9–12,23–26). This includes
rapidly differentiating CHF from other causes of dyspnea in
Figure 1. B-type natriuretic peptide (BNP) levels of patients diagnosed with congestive heart failure (CHF), baseline left ventricular dysfunction, pulmonary
disease, other cardiac disease and other noncardiac, nonpulmonary disease.
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patients presenting to the ED (12), screening patients for
LV dysfunction (24) and monitoring hemodynamically
guided treatment of CHF (26).
In the present study BNP was able to distinguish CHF
from pulmonary and other clinical presentations with a high
specificity, sensitivity and accuracy. Even in those patients
with comorbid conditions of CHF and COPD, BNP was
useful in distinguishing the reason for the visit to the ED. In
the 65 patients with both conditions, those with a current
COPD exacerbation had an average BNP of 47 pg/ml,
whereas those with current CHF had an average BNP of
731 pg/ml.
Multivariate analysis showed that assessing BNP levels
added to the diagnosis above and beyond these clinical tests
or physical findings such as chest X-ray findings, rales and
edema. When BNP was added to the data available, it still
was significant in improving the diagnosis of CHF, which is
seen as significance of p  0.001, 87% sensitivity, 95%
specificity and a 91% accuracy.
Other tests used to differentiate CHF from pulmonary
disease. While use of echocardiography and Swan-Ganz
catheterization may help differentiate CHF from pulmonary
dyspnea in specific settings, other tests have not fared so
well. These include peak expiratory flow (PEF) and dyspnea
differentiation index, which is the product of the PEF and
the partial pressure of arterial blood/1,000 (27). While some
positive results have been found, there is a large overlap in
values as well as failure to predict comorbidity states (27).
Peak expiratory flow rate has also been proposed as a way to
distinguish CHF from lung disease. However, values tend
to decrease with more severe forms of heart failure, limiting
its usefulness in this setting (28,29). Finally, end tidal CO2
measurements as well as breath sound auscultations have
also been proposed as a means to differentiate pulmonary
from cardiac dyspnea. Neither test has been able to perform
accurately enough to be of practical value (28,30).
Rational use of BNP in the urgent care setting. Several
confounding issues should be addressed if the rapid BNP
Figure 2. Receiver operating characteristic curve comparing the sensitivity and specificity of B-type natriuretic peptide (BNP) in differentiating congestive
heart failure (CHF) from non-CHF in patients presenting with dyspnea. Selected BNP values are indicated in pg/ml. Listed below the figure are accuracies
of various cut-points of BNP. AUC  area under curve and is significant, p  0.001.
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assay is to become standard practice in urgent care settings.
In some cases, patients have both cardiac and pulmonary
diseases occurring concurrently, such as when pneumonia
triggers CHF. In these settings, both a high BNP level and
consolidation on chest X-ray would be likely. This under-
scores that BNP is not a stand-alone test and that clinical
judgment always should be taken in the highest regard.
Patients who present with a COPD exacerbation, which
has triggered worsening cor pulmonale, may present with
dyspnea and signs of right ventricular volume overload
(including edema and ascites). In these patients BNP levels
are likely to be high (300 pg/ml to 600 pg/ml), though
usually not as high as cardiac dyspnea from elevated LV
end-diastolic pressure. Nagaya et al. (31) recently measured
hemodynamics and BNP levels in 44 patients with right
ventricular overload from pulmonary hypertension. The
mean BNP level in this group was 294 pg/ml and correlated
with indexes of pulmonary artery and right ventricular
Figure 3. Mean  SD for B-type natriuretic peptide (BNP) values in patients with various types of pulmonary disease. COPD  chronic obstructive
pulmonary disease; TB  tuberculosis.
Figure 4. B-type natriuretic peptide (BNP) levels in patients with a past history of pulmonary disease but a final diagnosis of acute congestive heart failure
(CHF), as well as patients with a past history of CHF but a final diagnosis of acute pulmonary disease. Data are expressed as mean  SE for BNP values.
COPD  chronic obstructive pulmonary disease.
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end-diastolic pressures, as well as with long-term changes in
hemodynamics. Thus, the positive predictive value of BNP
might decrease at values between 80 pg/ml to 300 pg/ml in
patients with possible right ventricular involvement. We
also had three patients with large pulmonary embolism
whose BNP levels were elevated into the 200 pg/ml to
300 pg/ml range, probably from acute right ventricular
pressure overload.
While the positive predictive value of BNP might be
mitigated in the above settings, the importance of a negative
predictive value of BNP in settings of acute dyspnea cannot
be overstated. For instance, an extremely ill patient who has
cardiogenic pulmonary edema on chest X-ray with a normal
BNP level likely has adult respiratory distress syndrome. A
patient with large cardiac silhouette on chest X-ray but who
has a normal BNP level could quite possibly have cardiac
tamponade.
Finally, there are several circumstances in which BNP
may be elevated for other reasons. Since patients who have
end-stage renal failure or who are on dialysis have elevated
BNP levels (32), diagnosing CHF in this population should
rely on more standard criteria. Also, in some patients
dyspnea may be the clinical manifestation of acute
myocardial infarction. B-type natriuretic peptide is also a
marker of necrosis and may be elevated in these patients
(23). Thus, if other features suggest myocardial infarction
(e.g., changes, chest pressure, etc.) cardiac markers should
be measured.
Study limitations. The study population was drawn from
the Veterans Affairs Medical Center and was 95% male.
Thus, these results need to be confirmed in a non-Veterans
Affairs population and with women. The patients studied
were those who came to the ED with symptoms, and results
may not be easily generalized to the outpatient setting.















Congestive heart failure 75 82 75 82 79
Coronary artery disease 69 56 53 72 62
Hypertension 78 44 50 74 58
Chronic obstructive pulmonary disease 40 60 42 58 52
Symptoms
Dyspnea 52 54 45 61 53
Dyspnea on exertion 85 32 48 75 54
Orthopnea 46 83 66 68 67
Paroxysmal nocturnal dyspnea 34 86 63 64 64
Cough 40 61 43 59 53
Edema 56 68 56 68 63
Signs
Fatigue and weight gain 31 70 42 58 54
Jugular venous pressure elevated 37 93 79 67 70
Rales 49 81 65 69 68
Wheezing 24 67 34 55 49
S3 13 99 90 61 63
S4 7 95 53 59 59
Murmurs 29 89 65 64 64
Chest X-ray and electrocardiogram
Heart size 53 90 80 70 73
Pleural effusion 28 92 74 61 63
Pulmonary venous hypertension 42 93 83 66 70
ST elevation 5 97 56 58 57
ST depression 10 94 53 58 58
New T-wave 24 92 69 62 63
Atrial fibrillation 16 98 83 61 63
Table 3. Multivariate Analysis







History of CHF 94.3 0.001 76 81 79
Chest X-ray enlarged 33.0 0.001 89 76 82
Jugular venous pressure 12.9 0.001 81 81 81
Pulmonary venous hypertension 6.4 0.011 68 91 80
Rales 4.3 0.038 74 88 82
B-type natriuretic peptide 119.6 0.001 87 95 91
CHF  congestive heart failure.
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Conclusions. The rapid measurement of the BNP concen-
tration in the blood appears to be a sensitive and specific test
for differentiating patients with CHF from primary pulmo-
nary causes of dyspnea in acute care settings. If further
studies validate our exploratory investigation, it is possible
that BNP may prove to be a cost-effective addition to the
diagnostic armamentarium of acute care physicians.
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